Claims for Patent: 9,173,885

Summary for Patent: 9,173,885

Title:	Inhibitors
Abstract:	The invention relates to novel pyrrolidine derivatives of formula (I): ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
Inventor(s):	Heiser; Ulrich (Halle/Saale, DE), Ramsbeck; Daniel (Halle/Saale, DE), Sommer; Robert (Halle/Saale, DE), Meyer; Antje (Halle/Saale, DE), Hoffmann; Torsten (Halle/Saale, DE), Boehme; Livia (Halle/Saale, DE), Demuth; Hans-Ulrich (Halle/Saale, DE)
Assignee:	PROBIODRUG AG (Halle/Saale, DE)
Application Number:	13/910,702
Patent Claims:	1. A method of treatment of a disease selected from the group consisting: inflammatory host responses, impaired humoral and cell-mediated immune responses, leukocyte adhesion and migration processes in the endothelium, multiple sclerosis, Guillain-Barre syndrome, chronic inflammatory demyelinizing polyradiculoneuropathy, mild cognitive impairment, Alzheimer's disease, Familial British Dementia, Familial Danish Dementia, neurodegeneration in Down Syndrome, Huntington's disease, rheumatoid arthritis, atherosclerosis, pancreatitis and restenosis, which comprises administering to a subject an effective amount of a compound of formula (I) or a pharmaceutical composition comprising a compound of formula (I), wherein said compound of formula (I) is the compound: ##STR00326## or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein: (a) R.sup.1 represents heteroaryl, -carbocyclyl-heteroaryl, -C.sub.2-6alkenylheteroaryl, --C.sub.1-6alkylheteroaryl, or (CH.sub.2).sub.aCR.sup.5R.sup.6(CH.sub.2).sub.bheteroaryl wherein a and b independently represent integers 0-5 provided that a+b =0-5 and R.sup.5 and R.sup.6 are alkylene which together with the carbon to which they are attached form a C.sub.3-C.sub.5 cycloalkyl group; in which any of aforesaid heteroaryl groups may optionally be substituted by one or more groups selected from C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl, C.sub.1-6haloalkyl, --C.sub.1-6thioalkyl, --SOC.sub.1-4alkyl, --SO.sub.2C.sub.1-4alkyl, C.sub.1-6alkoxy-, --O--C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl, --SO.sub.2C.sub.3-8cycloalkyl, --SOC.sub.3-6cycloalkyl, C.sub.3-6alkenyloxy-, C.sub.3-6alkynyloxy-, --C(O)C.sub.1-6alkyl, --C(O)OC.sub.1-6alkyl, C.sub.1-6alkoxy-C.sub.1-6alkyl-, nitro, halogen, cyano, hydroxyl, --C(O)OH, --NH.sub.2, --NHC.sub.1-4alkyl, --N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --C(O)N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --C(O)NH.sub.2, --C(O)NH(C.sub.1-4alkyl) and --C(O)NH(C.sub.3-10cycloalkyl); and in which any of aforesaid carbocyclyl groups may optionally be substituted by one or more groups selected from C.sub.1-4alkyl, oxo, halogen and C.sub.1-4alkoxy; (b) R.sup.2 and R.sup.3 are independently selected as follows, (i) R.sup.2 represents (1) H, C.sub.1-8alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, --C.sub.1-4alkylaryl, --C.sub.1-4alkylheteroaryl, --C.sub.1-4alkylcarbocyclyl or --C.sub.1-4alkylheterocyclyl; in which any of aforesaid aryl and heteroaryl groups may optionally be substituted by one or more groups selected from C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl, C.sub.1-6haloalkyl, --C.sub.1-6thioalkyl, --SOC.sub.1-4alkyl, --SO.sub.2C.sub.1-4alkyl, C.sub.1-6alkoxy-, --O--C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl, --SO.sub.2C.sub.3-8cycloalkyl, --SOC.sub.3-6cycloalkyl, C.sub.3-6alkenyloxy-, C.sub.3-6alkynyloxy-, --C(O)C.sub.1-6alkyl, --C(O)OC.sub.1-6alkyl, C.sub.1-6alkoxy-C.sub.1-6alkyl-, C.sub.1-6alkoxy-C.sub.1-6alkoxy-, nitro, halogen, haloC.sub.1-6alkyl, haloC.sub.1-6alkoxy, cyano, hydroxyl, --C(O)OH, --NH.sub.2, --NHC.sub.1-4alkyl, --N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --N(C.sub.1-4alkyl)(C.sub.1-4alkyl)-N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --C.sub.1-4alkyl-N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --C.sub.1-4alkoxy-N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --N(C.sub.3-8cycloalkyll)(C.sub.3-8cycloalkyl), --N(--C.sub.1-6alkyl-C.sub.1-6alkoxy)(-C.sub.1-6alkyl-C.sub.1-6alkoxy), --C(O)N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --C(O)NH.sub.2, --C(O)NH(C.sub.1-4alkyl) and --C(O)NH(C.sub.3-10cycloalkyl); and in which any of aforesaid carbocyclyl and heterocyclyl groups may optionally be substituted by one or more groups selected from C.sub.1-4alkyl, oxo, halogen, --C(O)C.sub.1-6alkyl and C.sub.1-4alkoxy; or (2) phenyl substituted by phenyl, phenyl substituted by a monocyclic heteroaryl group, phenyl substituted by phenoxy, phenyl substituted by heterocyclyl, phenyl substituted by heterocyclyl wherein said heterocyclyl is substituted by phenyl, phenyl substituted by --O--C.sub.1-4alkyl-heterocyclyl, phenyl substituted by benzyloxy, phenyl substituted by carbocyclyl, phenyl substituted by carbocyclyl wherein said carbocyclyl is substituted by heterocyclyl, phenyl substituted by --O-carbocyclyl, heterocyclyl substituted by phenyl, carbocyclyl substituted by phenyl, phenyl fused to carbocyclyl, phenyl fused to heterocyclyl, --C.sub.1-4alkyl(phenyl substituted by phenyl), --C.sub.1-4alkyl(phenyl substituted by a monocyclic heteroaryl group), --C.sub.1-4alkyl(phenyl substituted by a monocyclic heterocyclyl group), --C.sub.1-4alkyl(phenyl substituted by an --O-carbocyclyl group), --C.sub.1-4alkyl(phenyl substituted by benzyloxy), --C.sub.1-4alkyl(optionally substituted phenyl fused to optionally substituted carbocyclyl or --C.sub.1-4alkyl(optionally substituted phenyl fused to optionally substituted heterocyclyl); in which any of aforesaid phenyl, benzyloxy and heteroaryl groups may optionally be substituted by one or more groups selected from C.sub.1-4alkyl, halogen and C.sub.1-4alkoxy, and in which any of aforesaid carbocyclyl and heterocyclyl groups may optionally be substituted by one or more groups selected from methyl, phenyl, oxo, halogen, hydroxyl and C.sub.1-4alkoxy; and (ii) R.sup.3 represents H, --C.sub.1-4alkyl or aryl; in which aforesaid aryl may optionally be substituted by one or more groups selected from C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl, C.sub.1-6haloalkyl, --C.sub.1-6thioalkyl, --SOC.sub.1-4alkyl, --SO.sub.2C.sub.1-4alkyl, C.sub.1-6alkoxy-, --O--C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl, --SO.sub.2C.sub.3-8cycloalkyl, --SOC.sub.3-6cycloalkyl, C.sub.3-6alkenyloxy-, C.sub.3-6alkynyloxy-, --C(O)C.sub.1-6alkyl, --C(O)OC.sub.1-6alkyl, C.sub.1-6alkoxy-C.sub.1-6alkyl-, nitro, halogen, cyano, hydroxyl, --C(O)OH, --NH.sub.2, --NHC.sub.1-4alkyl, --N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --C(O)N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --C(O)NH.sub.2, --C(O)NH(C.sub.1-4alkyl) and, --C(O)NH(C.sub.3-10cycloalkyl); or (c) R.sup.2 and R.sup.3 are jointly selected as follows, (1) R.sup.2 and R.sup.3 are joined to form a carbocyclyl ring which is optionally substituted by one or more C.sub.1-2alkyl groups; (2) R.sup.2 and R.sup.3 are joined to form a carbocyclyl ring which is fused to phenyl, wherein aforesaid carbocyclyl and/or phenyl may optionally be substituted by one or more groups selected from C.sub.1-4alkyl, halogen and C.sub.1-4alkoxy; or (3) R.sup.2 and R.sup.3 are joined to form a carbocyclyl ring which is fused to monocyclic heteroaryl, wherein aforesaid carbocyclyl and/or heteroaryl may optionally be substituted by one or more groups selected from C.sub.1-4alkyl, halogen and C.sub.1-4alkoxy; (d) X and Z are independently selected as follows, (i) X represents C.dbd.O, O, CR.sup.7R.sup.8, --O--CH.sub.2-- or --CH.sub.2--CH.sub.2--; and (ii) Z represents --N--R.sup.4, O or CHR.sup.10, such that when X represents O, Z must represent CHR.sup.10; or (e) X and Z are jointly selected to represent two adjacent carbon atoms of a phenyl ring which is fused in that position and which is optionally substituted by one or more halogen or C.sub.1-2alkyl groups; and (f) Y represents CHR.sup.9, C.dbd.O or C.dbd.S; wherein, R.sup.4 represents H, --C.sub.1-8alkyl, --C(O)C.sub.1-6alkyl or --NH.sub.2; R.sup.7 and R.sup.8 independently represent H, --C.sub.1-4alkyl or aryl; in which said aforesaid aryl may be optionally substituted by C.sub.1-6alkyl, C.sub.2-6alkenyl, C.sub.2-6alkynyl, C.sub.1-6haloalkyl, --C.sub.1-6thioalkyl, --SOC.sub.1-4alkyl, --SO.sub.2C.sub.1-4alkyl, C.sub.1-6alkoxy-, --O--C.sub.3-8cycloalkyl, C.sub.3-8cycloalkyl, --SO.sub.2C.sub.3-8cycloalkyl, --SOC.sub.3-6cycloalkyl, C.sub.3-6alkenyloxy-, C.sub.3-6alkynyloxy-, --C(O)C.sub.1-6alkyl, --C(O)OC.sub.1-6alkyl,C.sub.1-6alkoxy-C.sub.1-6alkyl-, nitro, halogen, cyano, hydroxyl, --C(O)OH, --NH.sub.2, --NHC.sub.1-4alkyl, --N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --C(O)N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --C(O)NH.sub.2, --C(O)NH(C.sub.1-4alkyl) and, --C(O)NH(C.sub.3-10cycloalkyl); and R.sup.9 and R.sup.10 independently represent H or methyl; provided that the moiety --Y--Z--X-- represents a moiety other than --C(.dbd.O)--N(--R.sup.4)--C(.dbd.O)-- or --C(.dbd.S)--N(--R.sup.4)--C(.dbd.O)--. 2. The method according to claim 1, wherein R.sup.1 represents unsubstituted heteroaryl or heteroaryl optionally substituted by one or more C.sub.1-6 alkyl, halogen or C.sub.1-6 haloalkyl groups. 3. The method according to claim 2, wherein R.sup.1 represents a phenyl ring fused to a 5-membered heteroaryl ring wherein R.sup.1 is linked to the core of formula (I) through the phenyl ring. 4. The method according to claim 2 wherein R.sup.1 represents ##STR00327## wherein: B represents a bond, --CH.sub.2--, --CH.sub.2--CH.sub.2--, --CH(Me)--, --CH(Me)--CH.sub.2-- or --CH.sub.2--CH(Me)-- and R.sup.14 and R.sup.15 independently represent H or C.sub.1-2alkyl. 5. The method according to claim 4 wherein R.sup.1 represents ##STR00328## 6. The method according to claim 5 wherein R.sup.1 represents ##STR00329## 7. The method according to claim 1, wherein R.sup.2 represents aryl, heteroaryl, phenyl substituted by phenyl, phenyl fused to heterocyclyl or R.sup.2 and R.sup.3 are joined to form a carbocyclyl ring which is fused to phenyl; the aforesaid aryl, heteroaryl, phenyl, heterocyclyl and carbocyclyl optionally being substituted. 8. The method according to claim 7 wherein R.sup.2 represents aryl, heteroaryl, phenyl substituted by phenyl or phenyl fused to heterocyclyl; the aforesaid aryl, heteroaryl, phenyl and heterocyclyl optionally being substituted. 9. The method according to claim 8 wherein R.sup.2 represents optionally substituted aryl. 10. The method according to claim 9 wherein R.sup.2 represents phenyl substituted by one or more groups selected from C.sub.1-6alkyl, C.sub.1-6 alkoxy, hydroxyl, haloC.sub.1-6 alkyl, haloC.sub.1-6 alkoxy, halogen, C.sub.1-6alkoxy-C.sub.1-6alkyl-, C.sub.1-6alkoxy-C.sub.1-6alkoxy-, --N(C.sub.1-4alkyl)(C.sub.1-4alkyl)--N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --N(C.sub.3-8cycloalkyll)(C.sub.3-8cycloalkyl), --C.sub.1-4alkyl-N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --C.sub.1-4alkoxy-N(C.sub.1-4alkyl)(C.sub.1-4alkyl), --N(--C.sub.1-6alkyl-C.sub.1-6alkoxy)(--C.sub.1-6alkyl-C.sub.1-6alkoxy). 11. The method according to claim 10 wherein R.sup.2 represents phenyl substituted by one or more groups selected from methyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, isopropyloxy, hydroxyl, trifluoromethyl, tetrafluoroethyloxy, chlorine, fluorine, --(CH.sub.2).sub.3--OMe, --O--(CH.sub.2).sub.2OMe, --N(Me)--(CH.sub.2).sub.2--N(Me).sub.2, --N(ethyl)(ethyl)), --N(cyclopropyl)(cyclopropyl)), --(CH.sub.2).sub.3--N(methyl)(methyl), --O(CH.sub.2).sub.2--N(methyl)(methyl)), --N((CH.sub.2).sub.2OMe)(CH.sub.2).sub.2OMe)). 12. The method according to claim 11 wherein R.sup.2 represents phenyl substituted by one or more C.sub.1-6alkoxy groups. 13. The method according to claim 12 wherein R.sup.2 represents phenyl substituted by one or more groups selected from methoxy, ethoxy, propoxy, butoxy, pentoxy or isopropyloxy. 14. The method according to claim 13 wherein R.sup.2 represents phenyl substituted by a propoxy group. 15. The method according to claim 1, wherein R.sup.3 represents H. 16. The method according to claim 1, wherein R.sup.4 represents H. 17. The method according to claim 1, wherein X represents CR.sup.7R.sup.8, Y represents C.dbd.O and Z represents --N--R.sup.4. 18. The method according to claim 16, wherein X represents CH.sub.2, Y represents C.dbd.O and Z represents --NH. 19. The method according to claim 1, wherein X represents C.dbd.O, Y represents CHR.sup.9 and Z represents --N--R.sup.4. 20. The method according to claim 1, wherein X represents CR.sup.7R.sup.8, Y represents C.dbd.O and Z represents O. 21. The method according to claim 1, wherein X represents CR.sup.7R.sup.8, Y represents CHR.sup.9 and Z represents CHR.sup.10. 22. The method according to claim 1, wherein X represents CR.sup.7R.sup.8, Y represents C.dbd.O and Z represents CHR.sup.10. 23. The method according to claim 1, wherein X and Z represent two adjacent carbon atoms of a phenyl ring which is fused in that position and is optionally substituted by one or more halogen or C.sub.1-2alkyl groups and Y represents C.dbd.O. 24. The method according to claim 1, wherein X represents --O--CH.sub.2--, Y represents CO and Z represents CHR.sup.10. 25. The method according to claim 1, wherein X represents --CH.sub.2--CH.sub.2--, Y represents CO and Z represents O. 26. The method according to claim 1, wherein said compound of formula (I) is one of examples 1 to 109, 120 to 235 or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers. 27. The method according to claim 1, wherein said compound of formula (I) is one of examples 12 to 14 or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers. 28. The method according to claim 2, wherein C.sub.1-6alkyl is methyl, halogen is fluorine, or C.sub.1-6haloalkyl is trifluoromethyl. 29. The method according to claim 1 for the treatment or prevention of a disease selected from the group consisting of mild cognitive impairment, Alzheimer's disease, Familial British Dementia, Familial Danish Dementia, neurodegeneration in Down Syndrome and Huntington's disease. 30. The method according to claim 1 for the treatment or prevention of a disease selected from the group consisting of rheumatoid arthritis, atherosclerosis, pancreatitis and restenosis. 31. The method of claim 1, wherein said pharmaceutical composition comprises additionally at least one compound, selected from the group consisting of neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs and anti-multiple sclerosis drugs. 32. The method of claim 31, wherein said pharmaceutical composition comprises additionally at least one compound, selected from the group consisting of PEP-inhibitors, LiCI, inhibitors of inhibitors of DP IV or DP IV-like enzymes, acetylcholinesterase (ACE) inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases, inhibitors of neutral endopeptidase, inhibitors of Phosphodiesterase-4 (PDE-4), TNFalpha inhibitors, muscarinic M1 receptor antagonists, NMDA receptor antagonists, sigma-1 receptor inhibitors, histamine H3 antagonists, immunomodulatory agents, immunosuppressive agents or an agent selected from the group consisting of antegren (natalizumab), Neurelan (fampridine-SR), campath (alemtuzumab), IR 208, NBI 5788/MSP 771 (tiplimotide), paclitaxel, Anergix.MS (AG 284), SH636, Differin (CD 271, adapalene), BAY 361677 (interleukin-4), matrix-metalloproteinase-inhibitors, interferon-tau (trophoblastin) and SAIK-MS.

Details for Patent 9,173,885

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2023-07-16
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2023-07-16
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2023-07-16
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004		2023-07-16
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004		2023-07-16